Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Financings Of The Fortnight: VCs May Be Up Against Trend Of Eliminating The “Middle-Man”

This article was originally published in The Pink Sheet Daily

Executive Summary

Plus news on recent financings by PharmAria, Inception 3, Longitude Capital, Kythera and Intercept.

You may also be interested in...



Genocea Gets An Injection Of Capital As Early-Stage Studies Progress

The vaccine developer tapped investors for a third round of financing as its lead programs begin clinical trials.

Mid-To-Late-Stage Investor Longitude Capital Closes $385M Second Fund

A history of strong returns from the firm, which backs both private and public health care companies, compelled existing investors to return for a new fund. Still, Longitude retained a placement agent to find new limited partners as an “insurance policy.”

Roche Enters Hearing-Loss Space In Risk-Sharing Venture With Inception, Versant

The newly formed Inception 3 will work to bring small molecule candidates for hearing loss, based on technology licensed from Stanford University, to IND-filing stage, at which point Roche will have the option to buy out the program.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS073384

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel